@article{d96941a883204dddb6bd2b43fc4c1dd6,
title = "Disease progression in multiple sclerosis: A Literature Review Exploring Patient Perspectives",
keywords = "Communication, Disease progression, Multiple sclerosis, Patient engagement, Shared decisionmaking",
author = "Celius, {Elisabeth G.} and Heidi Thompson and Maija Pontaga and Dawn Langdon and Alice Laroni and Stanca Potra and Trishna Bharadia and David Yeandle and Jane Shanahan and {van Galen}, Pieter and Nektaria Alexandri and J{\"u}rg Kesselring",
note = "Funding Information: The MS in the 21st Century initiative is financially supported by Merck KGaA, Darmstadt, Germany . Secretariat support and editorial input were provided by Cello Health Communications. Search result sorting and medical writing assistance was provided by Owen W ebb, Cello Health Communications. Secretariat support, editorial input and medical writing assistance were funded by Merck KGaA, Darmstadt, Germany . Funding Information: Elisabeth G Celius has received honoraria for advisory boards and/or speaker honoraria from Almirall, Biogen, Merck KGaA, Roche, Novartis, Genzyme and T eva, and unrestricted research grants from Novartis and Genzyme, and reports personal fees from Biogen, Sanofi, and Novartis, and personal fees from Roche and Merck KGaA, outside the submitted work. Heidi Thompson has received honoraria for advisory board participation and travel grants from Merck KGaA and Biogen. Dawn Langdon has received research grants from Bayer , Merck KGaA, Novartis, and Biogen, all paid to her institution and has participated in speakers{\textquoteright} bureaus for Bayer , Merck KGaA, Almirall, Excemed, T eva, Roche, Novartis, Biogen, and Sanofi, has received consultancy honoraria from Novartis, Bayer , Merck KGaA, Biogen, T eva, and Sanofi, and reports grants and personal fees from Merck KGaA and Novartis, and personal fees from TEV A, Bayer , and Biogen, outside the submitted work. Alice Laroni has received personal compensation from Novartis, Sanofi Genzyme, Biogen, Merck KGaA, Roche and T eva for public speaking and advisory boards and has received research grants from the Italian Ministry of Health, the Italian Ministry of University , and The Italian MS Foundation, and reports personal fees from Biogen, Merck KGaA and Novartis, non-financial support from Roche, grants from Fondazione Italiana sclerosi multiplaoutside the submitted work. T rishna Bharadia reports personal fees from Merck KGaA, Actelion, Roche, Sanofi-Genzyme, Envision Pharma, T eva, Biogen, Novartis, Blue Latitude Health, and talkHealth, outside the submitted work, and is Ambassador for MS Society UK (voluntary position), Patron for Chilterns MS Centre (voluntary position), and Patron for Cambs Therapy Centre (voluntary position). Maija Pontaga, Stanca Potra, David Y eandle, Jane Shanahan, and J{\"u}rg Kesselring have received honoraria from Merck KGaA for MS in the 21st Century activities. Pieter van Galen has received honoraria from Merck KGaA for MS in the 21st Century activities and has received consulting and speaking fees from Novartis, Merck KGaA, Celgene R&D Sarl, F . Hoffman-La Roche, NV Roche SA, Mylan GMBH and Excemed. Nektaria Alexandri is an employee of Merck KGaA. The authors report no other potential conflicts of interest for this work. Publisher Copyright: {\textcopyright} 2021 Celius et al. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = jan,
day = "8",
doi = "10.2147/PPA.S268829",
language = "English",
volume = "15",
pages = "15--27",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd",
}
